Please assess the completion status of the following clinical trial:

Trial Title: SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria~* Subjects in general good health in the opinion of the investigator as determined by medical history, vital signs and a physical examination.~* Negative human leukocyte antigen (HLA) -B27 and no history of reactive arthritis~* Negative HIV, Hepatitis B and Hepatitis C serology tests.~* Blood levels of Shigella flexneri 2a LPS IgG antibodies ≤ percentile 80~* No known history of alcohol abuse~Exclusion criteria~* Subjects with a history of clinically significant gastrointestinal disorders or with any history of frequent diarrhea, nausea or emesis, regardless of etiology.~* Individuals with immunosuppressive diseases or under immunosuppressive therapy~* History of culture-proven S. flexneri.~* Individuals who have household contact with/and /or intimate exposure to an individual with laboratory confirmed S. flexneri.~* Having travelled in countries/areas highly endemic for S. flexneri within 3 months prior to enrolment.~* Previous participation in any study in which a Shigella-vaccine candidate was administered.~* Known contraindication, hypersensitivity and/or allergy to the investigational product or its excipients.~* Known hypersensitivity and/or allergy to any drug or vaccine~* Women who are pregnant or are breast-feeding, or are of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- vaccine dose 1 (Type: EXPERIMENTAL): SF2a-TT15 vaccine, 2 μg
- vaccine dose 1+ adjuvant (Type: EXPERIMENTAL): SF2a-TT15 vaccine, 2 μg + alum
- vaccine dose 2 (Type: EXPERIMENTAL): SF2a-TT15 vaccine, 10 μg
- vaccine dose 2 + adjuvant (Type: EXPERIMENTAL): SF2a-TT15 vaccine, 10 μg + alum
- Placebo (Type: PLACEBO_COMPARATOR): Tris buffer
- Placebo + adjuvant (Type: PLACEBO_COMPARATOR): Tris buffer + Alum

Based on this trial design, predict the completion outcome and termination type (if applicable).